Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Futura MedicalFAMDF 3-Year EPS without NRI Growth Rate is 9.10% as of Dec. 2025, which is 1038% above its 10-year median of 0.80. The stock has 5 warning signs investors should review. Among 1,166 Biotechnology companies, Futura Medical ranks worse than 59.18% on this metric.
During the past 12 months, Futura Medical's average EPS without NRI Growth Rate was -475.00% per year.
During the past 3 years, the average EPS without NRI Growth Rate was 9.10% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EPS without NRI growth rate.
During the past 13 years, the highest 3-Year average EPS without NRI Growth Rate of Futura Medical was 32.10% per year. The lowest was -30.10% per year. And the median was 0.80% per year.
Futura Medical (OTCPK:FAMDF) 3-Year EPS without NRI Growth Rate Explanation
EPS without NRI is the amount of earnings without non-recurring items per outstanding share of the company's stock.
Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists Earnings per share without Non-Recurring Items, which better reflects the company's underlying performance.
Futura Medical 3-Year EPS without NRI Growth Rate Related Terms
FAMDF vs VRTX, REGN, RVMD: 3-Year EPS without NRI Growth Rate Comparison
For the Biotechnology subindustry, Futura Medical's 3-Year EPS without NRI Growth Rate, along with its competitors' market caps and 3-Year EPS without NRI Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Futura Medical 3-Year EPS without NRI Growth Rate vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Futura Medical's 3-Year EPS without NRI Growth Rate distribution charts can be found below:
* The bar in red indicates where Futura Medical's 3-Year EPS without NRI Growth Rate falls into.
Futura Medical 3-Year EPS without NRI Growth Rate Calculation
This is the 3-year average growth rate of EPS without NRI. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EPS without NRI growth rate.
What does a 3-Year EPS without NRI Growth Rate of 9.10% mean?
Futura Medical (FAMDF) has a 3-Year EPS without NRI Growth Rate of 9.10% as of Dec. 2025. 3-Year EPS without NRI Growth Rate is the 3-year average growth rate of EPS without NRI. View historical data for Futura Medical and its competitors. This is 1038% above median its historical median of 0.80. According to the industry distribution chart, Futura Medical ranks #690 out of 1166 companies in the Biotechnology industry, placing it in the top 59.2%.
Is Futura Medical's 3-Year EPS without NRI Growth Rate too high?
Futura Medical's current 3-Year EPS without NRI Growth Rate of 9.10% is 1038% above median its 10-year median of 0.80. The Biotechnology industry median 3-Year EPS without NRI Growth Rate is 16.20. Futura Medical's value of 9.10% is 43.8% below this industry median. Based on the distribution chart, Futura Medical ranks #690 out of 1166 companies in the Biotechnology industry, which is below the industry midpoint.
How does Futura Medical's 3-Year EPS without NRI Growth Rate compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Futura Medical ranks #690 out of 1166 companies for 3-Year EPS without NRI Growth Rate. This places Futura Medical in the lower half of its industry. The industry median 3-Year EPS without NRI Growth Rate is 16.20. Futura Medical's value of 9.10% is 43.8% below this benchmark. While the company's 10-year median is 0.80 vs. the industry median of 16.20, Futura Medical has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EPS without NRI Growth Rate for a Biotechnology company?
The median 3-Year EPS without NRI Growth Rate among Biotechnology companies is 16.20, based on 1,166 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EPS without NRI Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EPS without NRI Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Futura Medical's current 3-Year EPS without NRI Growth Rate of 9.10% is 43.8% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EPS without NRI Growth Rate mean?
A high 3-Year EPS without NRI Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EPS without NRI Growth Rate is the 3-year average growth rate of EPS without NRI. View historical data for Futura Medical and its competitors. For the Biotechnology industry, the median 3-Year EPS without NRI Growth Rate is 16.20 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Futura Medical's current 3-Year EPS without NRI Growth Rate is 9.10%, which is 1038% above median its own 10-year median of 0.80. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Futura Medical stock overvalued right now?
Based on GuruFocus' analysis, Futura Medical (FAMDF) is currently considered Possible Value Trap. The stock's GF Value™ is $0.08, compared to a current price of $0.00 — trading 95% below its estimated fair value. The current 3-Year EPS without NRI Growth Rate is 9.10%, which is 1038% above median its 10-year median of 0.80 and 43.8% below the Biotechnology industry median of 16.20. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EPS without NRI Growth Rate calculated?
3-Year EPS without NRI Growth Rate is calculated from a company's financial statements. For Futura Medical (FAMDF), the current 3-Year EPS without NRI Growth Rate is 9.10% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Futura Medical PLC is engaged in the development and commercialization of sexual health products. Its product Eroxon is a treatment for erectile dysfunction. Geographically, the company derives the majority of its revenue from the United Kingdom and the European Union.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FAMDF has been successfully added to your 
